for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment

TOKYO, June 15 (Reuters) - Japan’s Daiichi Sankyo Co said on Tuesday it was halting development of an existing drug for the treatment of COVID-19.

Daiichi Sankyo in March started a clinical trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients. The company said in a statement it was discontinuing the trial without citing a reason. The Nikkei newspaper reported that there were safety concerns.

Nafamostat is used in the treatment of pancreatitis and has antiviral properties.

Reporting by Rocky Swift, editing by Louise Heavens

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up